VSBC VITASPRING BIOMEDICAL CO. LTD.

Overview and Growth

In fiscal 2026, VITASPRING BIOMEDICAL CO. LTD. recorded $0.00 of revenue, net loss of $415.37K, and an operating cash outflow of $2.69K. Diluted earnings per share were $0.00, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 207.03M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 0.0% higher than fiscal 2025, when diluted shares averaged 207.03M, adding context to the EPS comparison. Total assets stood at $14.68K, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

Gross profit was $0.00, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The reported operating result was an operating loss of $385.41K, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $415.37K after operating, financing, tax, and other recognized items. EBITDA was negative $375.45K, showing a deficit before interest, taxes, depreciation, and amortization. Before income taxes, the company recorded a loss of $385.41K, bridging the operating result to the final net loss. The company recognized $29.96K of income tax for the period, completing the transition from pretax income to net income. The net loss narrowed to $415.37K from $774.92K in fiscal 2025.

Liquidity and Capital Structure

At period end, the $14.68K asset base was financed through $4.45M of liabilities and -$4.43M of equity. The company reported negative equity of -$4.43M, a capital deficit that reduces its ability to absorb losses through book equity. At period end, current assets of $10.53K compared with current liabilities of $4.45M, defining the company’s short-term resource position. The current ratio was 0.0x; current liabilities exceeded current assets, leaving a short-term liquidity deficit. Cash and equivalents totaled $2.08K, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 0.0%, excluding receivables and other current assets. Measured against total assets, cash and equivalents represented 14.2%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 2.1% from $14.38K in fiscal 2025, leaving current total assets higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $2.69K, showing that operations absorbed cash during the period. Cash absorbed by operations decreased from $14.68K in fiscal 2025 to $2.69K.

Based on the annual report for the fiscal year ending Jan 31, 2026. Analysis generated Oct 21, 2026.